ClinicalTrials.gg
RecruitingNCT04847115Updated Apr 29, 2024

Treatment of Fifth Metatarsal Zone 3 Fractures

An interventional study of Operative and Walking boot orthosis in Fractures, Stress and Metatarsal Fracture, sponsored by Ostfold Hospital Trust. Recruiting at 3 sites in Norway. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-04-29.

Sponsored by Ostfold Hospital Trust · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Mar 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started Apr 2021; still recruiting 5 years 7 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The fifth metatarsal is one of the bones where stress fractures can occur. Current literature provides support for both operative and non-operative treatment, but is mostly based on retrospective studies. One small randomized controlled trial reported faster recovery in the surgery group, but this study is probably subject to selection bias as well as underpowered design. There is a need to strengthen the knowledge base regarding treatment of stress fractures in the fifth metatarsal. This study seeks to answer whether osteosynthesis with an intramedullar screw fixation gives faster painfree weight bearing compared to non-operative treatment with a walking boot.

02

Conditions studied

  • Fractures, Stress
  • Metatarsal Fracture

Browse trials for

03

In context

Fractures, Stress

23 studies on the registry are indexed under Fractures, Stress; 4 are open to participants now.

This study's planned enrollment of 100 is close to the median of 110 across 17 interventional studies indexed under Fractures, Stress.

Browse Fractures, Stress studies →

Lead sponsor

Ostfold Hospital Trust is the lead sponsor of 50 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Zone 3 fracture

Exclusion criteria

Exclusion Criteria:

  • Neuropathy
  • Open fractures
  • High energy injuries
  • Associated injury in the same or opposite extremity that may affect treatment or rehabilitation
  • Pressure ulcer(s)
  • Lack of consent competence
  • Fracture radiologically confirmed more than six months ago
  • No possibility of follow-up at one of the study centers
  • Established pseudarthrosis
  • Medical condition that contraindicates surgery
  • Non-compliance
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Active comparator
    Operative

    The patients in this arm will be treated operatively with intramedullar screw osteosynthesis. In addition to this, they will weight bear as tolareted in a walking boot orthosis for six weeks.

    Procedure: Operative · Other: Walking boot orthosis

  • Active comparator
    Non-operative

    The patients in this arm will have non-operative treatment with a walking boot orthosis for six weeks. They will weight bear as tolerated

    Other: Walking boot orthosis

Interventions

  • ProcedureOperative

    Intramedullary screw fixation

    Also known as: Osteosynthesis

  • OtherWalking boot orthosis

    Non-operative treatment with walking boot orthosis for six weeks. The non-operative study arm will use walking boot orthosis only. The operative study arm will use walking boot orthosis as adjuvant treatment.

06

What researchers measure

Primary outcomes

  1. Pain free weight bearing

    Defined as Visual Analoge Scale below 3. The scale range is 0 to 10, where 0 means "no pain" and 10 means "worst pain".

    Time frame: 2 years

Secondary outcomes

  1. Palpatory pain

    Visual Analog Scale below 3

    Time frame: 2 years

  2. Radiological healing

    Time to radiological callus formation

    Time frame: 2 years

  3. Work status

    Time of sick leave

    Time frame: 2 years

  4. Refracture

    Rate of refractures

    Time frame: 2 years

  5. Delayed union

    Rate of delayed unions

    Time frame: 2 years

  6. Nonunions

    Rate of nonunions

    Time frame: 2 years

  7. Level of activity

    Time to normal activity level is resumed

    Time frame: 2 years

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2021 (actual). Primary completion is estimated for Mar 2026, 59 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2021
First posted
Apr 19, 2021
StartActual
Apr 10, 2021
Primary completionEst.
Mar 31, 2026
CompletionEst.
Mar 31, 2030
Last update
Apr 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04847115
Lead sponsor
Ostfold Hospital Trust
Responsible party
Sponsor
First posted
Apr 19, 2021
Start date
Apr 10, 2021
Primary completion
Mar 31, 2026 (estimated)
Completion
Mar 31, 2030 (estimated)
Last update
Apr 29, 2024

Study contacts

Marius Molund, PhD
Contact
marius.molund@so-hf.no
0047 90093988
Marius Molund, PhD
principal investigator · Ostfold HT

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion